Advance market commitment for pneumococcal vaccines: Putting theory into practice

Bulletin of the World Health Organization

Volumn 89, Issue 12, 2011, Pages 913-918

  Cernuschi, Tania ^a   Furrer, Eliane ^a   Schwalbe, Nina ^a   Jones, Andrew ^b   Berndt, Ernst R ^c   McAdams, Susan ^d  

^a GAVI Alliance Secretariat   (Switzerland)

^b CLINTON HEALTH ACCESS INITIATIVE   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d WORLD BANK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

DEVELOPING WORLD; DISEASE CONTROL; HEALTH RISK; PUBLIC HEALTH; VACCINE;

ARTICLE; DEVELOPING COUNTRY; DRUG COST; DRUG INDUSTRY; ECONOMIC ASPECT; FUNDING; IMMUNIZATION; INTERNATIONAL COOPERATION; VACCINE PRODUCTION;

HEALTH CARE COSTS; HEALTH CARE SECTOR; HUMANS; MOTIVATION; PHYSICIAN'S PRACTICE PATTERNS; PILOT PROJECTS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SWITZERLAND; WORLD HEALTH;

EID: 82555193635     PISSN: 00429686     EISSN: 15640604     Source Type: Journal    
DOI: 10.2471/BLT.11.087700     Document Type: Article

References (21)

1. Laxminarayan R, Chow J, Shahid-Salleset SA. Intervention cost-effectiveness: overview of main messages (Chapter 2). In: Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB et al., eds. Disease control priorities in developing countries, 2nd edition. New York: Oxford University Press; 2006. Available from: http://files.dcp2.org/pdf/DCP/DCP.pdf [accessed 27 September 2011].
2. Barder O, Kremer M, Levine R. Making markets for vaccines: ideas to action (Working group report). Washington DC: Center for Global Development; 2005. Available from: http://www.cgdev.org/section/initiatives/_archive/vaccinedevelopment/chapters [accessed 27 September 2011].
3. An Advance Market Commitment for pneumococcal vaccines (Joint donor statement). Geneva: GAVI Alliance; 2008. Available from: http://www. gavialliance.org/library/documents/amc/iwg-joint-donor-statement/ [accessed 27 September 2011].
4. GAVI Alliance Revised Co-financing Policy. Geneva: GAVI Alliance; 2010. Available from: http://www.gavialliance.org/library/gavi-documents/ policies/gavi-alliance-revised-co-financing-policy/ [accessed 27 September 2011].
5. Advance Market Commitment for pneumococcal vaccines (Annual Report 1 April 2010 - 31 March 2011). Geneva: GAVI Alliance; 2011. Available from: http://www.gavialliance.org/library/gavi-documents/amc/2011- pneumococcal-amc-annual-report/ [accessed 27 September 2011].
6. Target Product Profile (TPP) for the Advance Market Commitment. (AMC) for pneumococcal conjugate vaccines (Part 1), Master Table. Geneva: World Health Organization; 2008. Available from: http://www.gavialliance.org/ library/documents/amc/tpp-master-table/ [accessed 27 September 2011].
7. Target Product Profile (TPP) for the Advance Market Commitment. (AMC) for pneumococcal conjugate vaccines (Part 2), supplementary Information. Geneva: World Health Organization; 2008. Available from: http://www.gavialliance.org/library/documents/amc/tpp-supplementary-information/ [accessed 27 September 2011]
8. Investing in immunisation through the GAVI Alliance. the evidence base. Geneva: GAVI Alliance; 2011. Available from http://www.gavialliance.org/ library/publications/the-evidence-base/ [accessed 27 September 2011]
9. Immunization financing in developing countries and the international vaccine market. trends and issues. Manila: Asian Development Bank; 2001. Available from: http://www.who.int/immunization_delivery/new_vaccines/14.immunization_financingindevelopingcountries.pdf [accessed 27 September].
10. GAVI Alliance and International Bank for Reconstruction and Development. Offer agreement relating to the Advance Market Commitment for pneumococcal vaccines. Geneva: GAVI Alliance; 2011. Available from: http://www.gavialliance.org/library/documents/amc/revised-amc-offer-agreement/ [accessed 27 September 2011].
11. Advanced Market Commitments Independent Expert Committee Membership. Geneva: GAVI Alliance; 2006. Available from: http://www.gavialliance.org/library/documents/amc/independent-expert-committee-membership
12. Independent Expert Committee Recommendation for AMC Pilot (Executive summary). Geneva: GAVI Alliance; 2006. Available from: http://www.gavialliance.org/library/documents/amc/independent-expert-committee-recommendation-for-amc-pilot/ [accessed 27 September 2011].
13. Final minutes. In: GAVI Alliance Board meeting, Geneva, 16-17 June 2010. Geneva: GAVI Alliance; 2010. Available from: http://www.gavialliance. org/about/governance/gavi-board/minutes/2010/16-june/ [accessed 27 September 2011].
14. Snyder CM, Begor W, Berndt ER. Economic perspectives on the Advance Market Commitment for Pneumococcal Vaccines. Health Aff (Millwood) 2011;30:1508-17. doi:10.1377/hlthaff.2011.0403 PMID:21821567
15. Hargreaves JR, Greenwood B, Clift C, Goel A, Roemer-Mahler A, Smith R et al. Making new vaccines affordable: a comparison of financing processes used to develop and deploy new meningococcal and pneumococcal conjugate vaccines. Lancet. Early Online Publication, 9 June 2011.
16. CDC vaccine price list for Pfizer's PCV-13 (dated 18 July 2011). Available from: http://www.cdc.gov/vaccines/programs/vfc/cdc-vac-price-list.htm [accessed August 2011].
17. Plahte J. Tiered pricing of vaccines: a win-win-win situation, not a subsidy. Lancet Infect Dis 2005;5:58-63. doi:10.1016/S1473-3099(04)01255-1 PMID:15620562
18. Vivid Economics. Advance Market Commitments for low-carbon development: an economic assessment. London: United Kingdom Department for International Development; 2009. Available from: http://www.dfid.gov.uk/ r4d/PDF/Outputs/EcoDev_Misc/60743-Vivid_Econ_AMCs.pdf [accessed 27 September 2011].
19. Vivid Economics and GVEP International. A potential role for AMCs in promoting green mini-grids in Tanzania. London: United Kingdom Department for International Development; 2010. Available from: http://www.dfid.gov.uk/r4d/PDF/Outputs/EcoDev_Misc/60743-VividEconTanzaniaAMC.pdf [accessed 27 September 2011].
20. Vivid Economics and GVEP International. A potential role for an AMC in supporting dish/stirling concentrating solar power. London: United Kingdom Department for International Development; 2010. Available from: http://www.dfid.gov.uk/r4d/PDF/Outputs/EcoDev_Misc/60743-VividEconCSP_ AMC.pdf [accessed 27 September 2011].
21. Waning B, Diedrichsen E, Jambert E, Bärnighausen T, Li Y, Pouw M etal. The global pediatric antiretroviral market: analyses of product availability and utilization reveal challenges for development of pediatric formulations and HIV/AIDS treatment in children. BMC Pediatr 2010;10:74. doi:10.1186/1471-2431-10-74 PMID:20950492